Protected intellectual property. Clinical inspiration. Scientific collaboration.
Verion W.L.L. is advancing EP4526275 – ETCHING PROCESS as part of a broader translational innovation pathway linking clinical medicine, biomaterials research and responsible industrial collaboration.
Modern zirconia and ceramic biomaterials have transformed implantology and restorative dentistry through their favorable mechanical, biological and aesthetic characteristics.
At the same time, long-term clinical performance is increasingly understood not solely through material composition itself, but through the interaction between biomaterial surfaces and surrounding biological environments.
Surface engineering and controlled modification approaches therefore continue to represent important areas of scientific and translational investigation.
At Verion W.L.L., we believe future advances in zirconia and ceramic technologies will emerge through closer integration of clinical insight, scientific understanding and responsible innovation.
Patent Information Box
Field | Information |
Patent | EP4526275 |
Application No. | 23726937.8 |
Title | ETCHING PROCESS |
Status | Granted |
IP Holder | Verion W.L.L. |
Development | Laboratory evaluation and scientific exchange ongoing |
EP4526275 forms part of Verion’s broader commitment to clinician-led innovation and translational biomaterial development.
Current work is being advanced through protected scientific and strategic frameworks designed to support responsible evaluation and future collaboration opportunities.
The innovation pathway behind EP4526275 originated from practical clinical observations and challenges encountered in implantology and restorative treatment concepts.
As a clinician-founded innovation initiative, Verion W.L.L. believes meaningful medical and biomaterial innovation often begins where clinical experience and scientific inquiry intersect.
Rather than pursuing technology as an isolated technical exercise, our approach emphasizes translational pathways capable of connecting medicine, research and industrial expertise.
Scientific progress rarely develops in isolation.
Verion W.L.L. actively supports interdisciplinary and translational collaboration models connecting clinicians, academia and industrial innovation.
Current scientific exchange and collaboration include cooperation with:
• Prof. Fabian Hüttig
• Prof. Frank Rupp
at the University of Tübingen.
While laboratory activities and ongoing findings remain confidential at this stage, Verion W.L.L. strongly believes future advances in zirconia and advanced ceramic technologies require precisely these forms of scientific and clinical collaboration.
Verion W.L.L. does not position EP4526275 as a standalone patent transaction.
Instead, the technology is viewed as part of a broader translational development pathway exploring future scientific, industrial and biomaterial-related applications.
Protected intellectual property serves not as an endpoint, but as the foundation for responsible innovation, scientific dialogue and selective partnership development.
Verion W.L.L. is selectively exploring collaboration models involving scientific, industrial and translational partners interested in advanced ceramic and biomaterial innovation.
Joint exploration of translational pathways, material evaluation and potential industrial development opportunities.
Academic cooperation, laboratory research and scientific evaluation models supporting responsible innovation.
Clinician–academia–industry collaboration frameworks designed to connect medical reality with scientific and technological progress.
Technical details, laboratory findings and unpublished scientific work remain confidential and are discussed only within protected scientific or strategic collaboration frameworks.
This approach safeguards innovation integrity while supporting responsible and mutually beneficial partnership discussions.
Verion W.L.L. is selectively engaging with scientific and industrial partners interested in advanced zirconia surface technologies and biomaterial innovation.
The company welcomes strategic discussions with qualified research, clinical, laboratory and industry stakeholders to explore responsible evaluation, scientific exchange and future collaboration opportunities.
